Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1111/trf.16268 http://scihub22266oqcxt.onion/10.1111/trf.16268 33491194!8013621!33491194     free     free     free Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=33491194&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Transfusion 2021 ; 61 (4): 1181-1190 Nephropedia Template TP {{tp|p=33491194|t=2021. Correlation between SARS-COV-2 antibody screening by immunoassay and neutralizing antibody testing |pdf=|usr=}}{{33491194}} gab.com Text Correlation between SARS-COV-2 antibody screening by immunoassay and neutralizing antibody testing JO: Transfusion http://www.kidney.de/pget.php?&tw=1&pmid=33491194 #FOAvip BACKGROUND: The efficacy of convalescent plasma (CP), an alternative for the treatment of COVID-19, depends on high titers of neutralizing antibodies (nAbs), but assays for quantifying nAbs are not widely available. Our goal was to develop a strategy to predict high titers of nAbs based on the results of anti-SARS-CoV-2 immunoassays and the clinical characteristics of CP donors. STUDY DESIGN AND METHODS: A total of 214 CP donors were enrolled and tested for the presence of anti-SARS-CoV-2 antibodies (IgG) using two commercial immunoassays: EUROIMMUN (ELISA) and Abbott (Chemiluminescence). Quantification of nAbs was performed using the Cytopathic Effect-based Virus Neutralization test. Three criteria for identifying donors with nAbs >/= 1:160 were tested: - C1: Curve ROC; - C2: Conditional decision tree considering only the IA results and - C3: Conditional decision tree including both the IA results and the clinical variables. RESULTS: The performance of the immunoassays was similar referring to both S/CO and predictive value for identifying nAbs titers >/=1:160. Regarding the studied criteria for identifying CP donors with high nAbs titers: (a) C1 showed 76.1% accuracy if S/CO = 4.65, (b) C2 presented 76.1% accuracy if S/CO >/=4.57 and (c) C3 had 71.6% accuracy if S/CO was >/=4.57 or if S/CO was between 2.68-4.57 and the last COVID-19-related symptoms were recent (within 19 days). CONCLUSION: SARS-CoV-2 IgG immunoassays (S/CO) can be used to predict high anti-SARS-CoV-2 nAbs titers. This study has proposed different criteria for identifying donors with >/=1:160 nAbs titers, all with high efficacy. Twit Text FOAVip Correlation between SARS-COV-2 antibody screening by immunoassay and neutralizing antibody testing ????Transfusion http://www.kidney.de/pget.php?&tw=1&pmid=33491194 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33491194 #FOAvip English Wikipedia <ref>{{Cite pmid|33491194}}</ref> Correlation between SARS-COV-2 antibody screening by immunoassay and neutralizing antibody testing #MMPMID33491194 Mendrone-Junior A; Dinardo CL; Ferreira SC; Nishya A; Salles NA; de Almeida Neto C; Hamasaki DT; Facincani T; de Oliveira Alves LB; Machado RRG; Araujo DB; Durigon EL; Rocha V; Sabino EC Transfusion 2021[Apr]; 61 (4): 1181-1190 PMID33491194show ga BACKGROUND: The efficacy of convalescent plasma (CP), an alternative for the treatment of COVID-19, depends on high titers of neutralizing antibodies (nAbs), but assays for quantifying nAbs are not widely available. Our goal was to develop a strategy to predict high titers of nAbs based on the results of anti-SARS-CoV-2 immunoassays and the clinical characteristics of CP donors. STUDY DESIGN AND METHODS: A total of 214 CP donors were enrolled and tested for the presence of anti-SARS-CoV-2 antibodies (IgG) using two commercial immunoassays: EUROIMMUN (ELISA) and Abbott (Chemiluminescence). Quantification of nAbs was performed using the Cytopathic Effect-based Virus Neutralization test. Three criteria for identifying donors with nAbs >/= 1:160 were tested: - C1: Curve ROC; - C2: Conditional decision tree considering only the IA results and - C3: Conditional decision tree including both the IA results and the clinical variables. RESULTS: The performance of the immunoassays was similar referring to both S/CO and predictive value for identifying nAbs titers >/=1:160. Regarding the studied criteria for identifying CP donors with high nAbs titers: (a) C1 showed 76.1% accuracy if S/CO = 4.65, (b) C2 presented 76.1% accuracy if S/CO >/=4.57 and (c) C3 had 71.6% accuracy if S/CO was >/=4.57 or if S/CO was between 2.68-4.57 and the last COVID-19-related symptoms were recent (within 19 days). CONCLUSION: SARS-CoV-2 IgG immunoassays (S/CO) can be used to predict high anti-SARS-CoV-2 nAbs titers. This study has proposed different criteria for identifying donors with >/=1:160 nAbs titers, all with high efficacy. |*COVID-19 Serological Testing[MESH] |*COVID-19/blood/diagnosis[MESH] |Adult[MESH] |Antibodies, Neutralizing/*blood[MESH] |Antibodies, Viral/*blood[MESH] |Female[MESH] |Humans[MESH] |Immunoassay[MESH] |Immunoglobulin G/*blood[MESH] |Male[MESH] |Middle Aged[MESH]Correlation between SARS-COV-2 antibody screening by immunoassay and n(epmc).pdf DeepDyve Pubget Overpricing